CY2268B1 - Aqueous risperidone formulations - Google Patents

Aqueous risperidone formulations

Info

Publication number
CY2268B1
CY2268B1 CY0200019A CY0200019A CY2268B1 CY 2268 B1 CY2268 B1 CY 2268B1 CY 0200019 A CY0200019 A CY 0200019A CY 0200019 A CY0200019 A CY 0200019A CY 2268 B1 CY2268 B1 CY 2268B1
Authority
CY
Cyprus
Prior art keywords
risperidone formulations
aqueous
aqueous risperidone
formulations
risperidone
Prior art date
Application number
CY0200019A
Other languages
English (en)
Inventor
Ois Marc Karel Jozef Fran
Willy Maria Albert Carlo Dries
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2268(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY2268B1 publication Critical patent/CY2268B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY0200019A 1994-07-11 2002-04-25 Aqueous risperidone formulations CY2268B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/272,462 US5453425A (en) 1994-07-11 1994-07-11 Risperidone oral formulation
US08/429,435 US5616587A (en) 1994-07-11 1995-04-26 Aqueous risperidone formulations

Publications (1)

Publication Number Publication Date
CY2268B1 true CY2268B1 (en) 2003-07-04

Family

ID=26955530

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0200019A CY2268B1 (en) 1994-07-11 2002-04-25 Aqueous risperidone formulations

Country Status (37)

Country Link
US (3) US5453425A (ro)
EP (1) EP0769965B1 (ro)
JP (1) JP2872412B2 (ro)
KR (1) KR100212942B1 (ro)
CN (1) CN1148226C (ro)
AP (1) AP774A (ro)
AT (1) ATE206931T1 (ro)
AU (1) AU684193B2 (ro)
BG (1) BG63070B1 (ro)
BR (1) BR9508253A (ro)
CA (1) CA2194564C (ro)
CY (1) CY2268B1 (ro)
CZ (1) CZ285204B6 (ro)
DE (1) DE69523313T2 (ro)
DK (1) DK0769965T3 (ro)
EE (1) EE03426B1 (ro)
ES (1) ES2165918T3 (ro)
FI (1) FI116510B (ro)
HK (1) HK1010691A1 (ro)
HR (1) HRP950397B1 (ro)
HU (1) HU222352B1 (ro)
IL (1) IL114525A (ro)
MX (1) MX9700374A (ro)
MY (1) MY114389A (ro)
NO (1) NO320366B1 (ro)
NZ (1) NZ289432A (ro)
PH (1) PH31626A (ro)
PL (1) PL179972B1 (ro)
PT (1) PT769965E (ro)
RO (1) RO116778B1 (ro)
RU (1) RU2161965C2 (ro)
SI (1) SI9500220B (ro)
SK (1) SK282159B6 (ro)
TR (1) TR199500778A1 (ro)
TW (1) TW420615B (ro)
WO (1) WO1996001652A1 (ro)
ZA (1) ZA955720B (ro)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0729357T3 (da) 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004017975A1 (en) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
EP1615924A1 (en) * 2003-04-22 2006-01-18 Synthon B.V. Water soluble salts of risperidone
PE20050285A1 (es) 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
WO2006129160A2 (en) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
DE602006005423D1 (de) * 2005-06-29 2009-04-16 Verisfield Uk Ltd Pharmazeutische Zusammensetzungen von Risperidon in wässriger Lösung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP4922657B2 (ja) * 2006-05-09 2012-04-25 高田製薬株式会社 リスペリドン経口用液剤
WO2007138462A2 (en) * 2006-06-01 2007-12-06 Wockhardt Ltd Aqueous oral formulations of risperidone
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
US7776866B2 (en) * 2007-09-15 2010-08-17 Protia, Llc Deuterium-enriched risperidone
JP5825786B2 (ja) * 2007-12-19 2015-12-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 長時間作用型注入可能パリペリドンエステルに関連する投薬計画
EP3006023B1 (en) 2009-01-20 2019-06-26 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic acid and derivatives thereof to enhance the activity of a neuropharmaceutical
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
EP2763676B1 (en) * 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2965895C (en) 2014-11-07 2019-08-06 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
KR102338171B1 (ko) 2016-06-13 2021-12-09 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산리튬의 공-결정 및 그의 용도
KR20230093349A (ko) * 2016-09-23 2023-06-27 델포어, 인코포레이티드 소분자 치료제 화합물 조성물
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
RU2646812C1 (ru) * 2016-10-24 2018-03-07 Общество с ограниченной ответственностью "Трейдсервис" Жидкая лекарственная форма рисперидона и способ ее получения
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN107260662A (zh) * 2017-06-21 2017-10-20 南京正科医药股份有限公司 一种利培酮口服溶液及其制备方法
CN107441037A (zh) * 2017-08-16 2017-12-08 南京正科医药股份有限公司 一种利培酮口服溶液
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
FR2796273B1 (fr) * 1999-07-15 2003-09-12 Oreal Composition a phase grasse liquide gelifiee par un polyamide a groupements ester terminaux

Also Published As

Publication number Publication date
CA2194564A1 (en) 1996-01-25
PT769965E (pt) 2002-04-29
NO320366B1 (no) 2005-11-28
HU9700082D0 (en) 1997-02-28
FI970109A0 (fi) 1997-01-10
JPH09511751A (ja) 1997-11-25
CN1148226C (zh) 2004-05-05
RO116778B1 (ro) 2001-06-29
NO970051D0 (no) 1997-01-07
EE9700009A (et) 1997-08-15
FI116510B (fi) 2005-12-15
CZ285204B6 (cs) 1999-06-16
AP774A (en) 1999-10-28
NO970051L (no) 1997-01-07
JP2872412B2 (ja) 1999-03-17
CZ2797A3 (en) 1997-07-16
PL179972B1 (pl) 2000-11-30
SI9500220A (en) 1996-02-29
AU684193B2 (en) 1997-12-04
HU222352B1 (hu) 2003-06-28
ZA955720B (en) 1997-01-10
TR199500778A1 (tr) 1996-10-21
KR100212942B1 (ko) 1999-08-02
PL318132A1 (en) 1997-05-12
NZ289432A (en) 1998-05-27
USRE39181E1 (en) 2006-07-11
AP9700910A0 (en) 1997-01-31
SK2297A3 (en) 1997-09-10
DE69523313D1 (de) 2001-11-22
DK0769965T3 (da) 2002-02-04
SK282159B6 (sk) 2001-11-06
WO1996001652A1 (en) 1996-01-25
ATE206931T1 (de) 2001-11-15
EE03426B1 (et) 2001-06-15
DE69523313T2 (de) 2002-06-27
BG63070B1 (bg) 2001-03-30
TW420615B (en) 2001-02-01
HRP950397A2 (en) 1997-10-31
PH31626A (en) 1999-01-12
SI9500220B (sl) 2004-12-31
US5453425A (en) 1995-09-26
BR9508253A (pt) 1997-12-23
HUT76826A (en) 1997-11-28
EP0769965A1 (en) 1997-05-02
EP0769965B1 (en) 2001-10-17
MY114389A (en) 2002-10-31
CA2194564C (en) 1997-12-16
HRP950397B1 (en) 2002-04-30
RU2161965C2 (ru) 2001-01-20
US5616587A (en) 1997-04-01
MX9700374A (es) 1997-04-30
BG101106A (en) 1997-08-29
FI970109A (fi) 1997-01-10
AU2927595A (en) 1996-02-09
HK1010691A1 (en) 1999-06-25
KR970704472A (ko) 1997-09-06
CN1155247A (zh) 1997-07-23
IL114525A (en) 1999-06-20
ES2165918T3 (es) 2002-04-01
IL114525A0 (en) 1995-11-27

Similar Documents

Publication Publication Date Title
AP9700910A0 (en) Aqueous risperidone formulations
IL102177A0 (en) Aqueous formulations
ZA953236B (en) Pharmaceutical formulations
GB9404248D0 (en) Pharmaceutical formulations
AU1839897A (en) Aqueous caffeine dosage forms
GB9415450D0 (en) Aqueous compositions
GB9420708D0 (en) Aqueous compositions
GB9413542D0 (en) Pharmaceutical formulations
GB9404989D0 (en) Lipomimetric formulation
ZA924315B (en) Aqueous formulations.
GB9408419D0 (en) Formulations
GB9406050D0 (en) Formulations
GB9418802D0 (en) Aqueous compositions
GB9408164D0 (en) Pharmaceutical formulations
ZA953239B (en) Pharmaceutical formulations
GB9414216D0 (en) Pharmaceutical formulations
GB9401738D0 (en) Pharmaceutical formulations
GB9426113D0 (en) Pharmaceutical formulations
GB9408161D0 (en) Pharmaceutical formulations
GB9408163D0 (en) Pharmaceutical formulations
GB9408151D0 (en) Pharmaceutical formulations
GB9417953D0 (en) Pharmaceutical formulations
GB9419921D0 (en) Improved formulations
GB9417041D0 (en) Improved formulations
GB9412641D0 (en) Formulation